Ukpe Ajima, Rosemary Chioma Omeni, Johnson Ogoda Onah, Jane David, John Owunebe Ehoche
{"title":"尼日利亚中北部乔斯市某些品牌瑞舒伐他汀片剂的上市后质量评估","authors":"Ukpe Ajima, Rosemary Chioma Omeni, Johnson Ogoda Onah, Jane David, John Owunebe Ehoche","doi":"10.1186/s13065-025-01470-w","DOIUrl":null,"url":null,"abstract":"<div><p>Rosuvastatin is a synthetic statin medication approved for the management of lipid disorders and also for preventing cardiovascular disease in at-risk individuals. Generic rosuvastatin formulations have been developed which are comparatively lower in cost and also assumed to be bio-similar to the innovator brand Crestor<sup>®</sup>. The present study investigated the chemical and physical attributes together with the in vitro bioequivalence profiles of four generic brands of rosuvastatin calcium tablets marketed in Jos, Nigeria in comparison to the reference brand. The tablet dimensions (thickness and diameter), weight variation, friability, hardness, disintegration time and dissolution profiles were evaluated in accordance to standard procedures. The samples were also assayed using Ultraviolet–Visible spectrophotometry at wavelength of 242.5 nm in methanol. In vitro bioequivalence was evaluated by determining the difference (<span>\\({\\text{f}}_{1}\\)</span>) and similarity (<span>\\({\\text{f}}_{2}\\)</span>) factors. The generic brands all complied with the pharmacopoeial specifications for weight variation, friability and disintegration. In addition, the tablet brands tested all had active drug content ranging from 94.92 to 109.2% and released over 80% of rosuvastatin calcium within the first twenty minutes of the dissolution studies thereby complying with pharmacopoeial requirements for content and dissolution respectively. All brands had similarity factor (<span>\\({\\text{f}}_{2}\\)</span>) values ranging from 50 to 100 and difference factor (<span>\\({\\text{f}}_{1}\\)</span>) values between 0 to 15% at pH 6.6, thus implying that the brands can be used interchangeably with the innovator brand. The chemical and physical tests carried out reveal that the locally marketed brands of rosuvastatin calcium are of good quality and meet the required regulatory standards.</p></div>","PeriodicalId":496,"journal":{"name":"BMC Chemistry","volume":"19 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bmcchem.biomedcentral.com/counter/pdf/10.1186/s13065-025-01470-w","citationCount":"0","resultStr":"{\"title\":\"Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria\",\"authors\":\"Ukpe Ajima, Rosemary Chioma Omeni, Johnson Ogoda Onah, Jane David, John Owunebe Ehoche\",\"doi\":\"10.1186/s13065-025-01470-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Rosuvastatin is a synthetic statin medication approved for the management of lipid disorders and also for preventing cardiovascular disease in at-risk individuals. Generic rosuvastatin formulations have been developed which are comparatively lower in cost and also assumed to be bio-similar to the innovator brand Crestor<sup>®</sup>. The present study investigated the chemical and physical attributes together with the in vitro bioequivalence profiles of four generic brands of rosuvastatin calcium tablets marketed in Jos, Nigeria in comparison to the reference brand. The tablet dimensions (thickness and diameter), weight variation, friability, hardness, disintegration time and dissolution profiles were evaluated in accordance to standard procedures. The samples were also assayed using Ultraviolet–Visible spectrophotometry at wavelength of 242.5 nm in methanol. In vitro bioequivalence was evaluated by determining the difference (<span>\\\\({\\\\text{f}}_{1}\\\\)</span>) and similarity (<span>\\\\({\\\\text{f}}_{2}\\\\)</span>) factors. The generic brands all complied with the pharmacopoeial specifications for weight variation, friability and disintegration. In addition, the tablet brands tested all had active drug content ranging from 94.92 to 109.2% and released over 80% of rosuvastatin calcium within the first twenty minutes of the dissolution studies thereby complying with pharmacopoeial requirements for content and dissolution respectively. All brands had similarity factor (<span>\\\\({\\\\text{f}}_{2}\\\\)</span>) values ranging from 50 to 100 and difference factor (<span>\\\\({\\\\text{f}}_{1}\\\\)</span>) values between 0 to 15% at pH 6.6, thus implying that the brands can be used interchangeably with the innovator brand. The chemical and physical tests carried out reveal that the locally marketed brands of rosuvastatin calcium are of good quality and meet the required regulatory standards.</p></div>\",\"PeriodicalId\":496,\"journal\":{\"name\":\"BMC Chemistry\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://bmcchem.biomedcentral.com/counter/pdf/10.1186/s13065-025-01470-w\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s13065-025-01470-w\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1186/s13065-025-01470-w","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
瑞舒伐他汀是一种合成的他汀类药物,被批准用于治疗脂质紊乱,也用于预防高危人群的心血管疾病。瑞舒伐他汀的仿制制剂已经开发出来,成本相对较低,并且被认为与创新品牌Crestor®具有生物类似性。本研究考察了在尼日利亚乔斯市上市的瑞舒伐他汀钙片的4个仿制品牌的化学、物理特性和体外生物等效性,并与参比品牌进行了比较。按照标准程序评价片剂的尺寸(厚度和直径)、重量变化、脆性、硬度、崩解时间和溶出度。用紫外可见分光光度法测定样品在甲醇中波长为242.5 nm。通过测定差异因子(\({\text{f}}_{1}\))和相似因子(\({\text{f}}_{2}\))评估体外生物等效性。仿制药均符合药典重量变化、易碎性和崩解性的标准。此外,被检测的片剂品牌的活性药物含量均在94.92 - 109.2之间% and released over 80% of rosuvastatin calcium within the first twenty minutes of the dissolution studies thereby complying with pharmacopoeial requirements for content and dissolution respectively. All brands had similarity factor (\({\text{f}}_{2}\)) values ranging from 50 to 100 and difference factor (\({\text{f}}_{1}\)) values between 0 to 15% at pH 6.6, thus implying that the brands can be used interchangeably with the innovator brand. The chemical and physical tests carried out reveal that the locally marketed brands of rosuvastatin calcium are of good quality and meet the required regulatory standards.
Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria
Rosuvastatin is a synthetic statin medication approved for the management of lipid disorders and also for preventing cardiovascular disease in at-risk individuals. Generic rosuvastatin formulations have been developed which are comparatively lower in cost and also assumed to be bio-similar to the innovator brand Crestor®. The present study investigated the chemical and physical attributes together with the in vitro bioequivalence profiles of four generic brands of rosuvastatin calcium tablets marketed in Jos, Nigeria in comparison to the reference brand. The tablet dimensions (thickness and diameter), weight variation, friability, hardness, disintegration time and dissolution profiles were evaluated in accordance to standard procedures. The samples were also assayed using Ultraviolet–Visible spectrophotometry at wavelength of 242.5 nm in methanol. In vitro bioequivalence was evaluated by determining the difference (\({\text{f}}_{1}\)) and similarity (\({\text{f}}_{2}\)) factors. The generic brands all complied with the pharmacopoeial specifications for weight variation, friability and disintegration. In addition, the tablet brands tested all had active drug content ranging from 94.92 to 109.2% and released over 80% of rosuvastatin calcium within the first twenty minutes of the dissolution studies thereby complying with pharmacopoeial requirements for content and dissolution respectively. All brands had similarity factor (\({\text{f}}_{2}\)) values ranging from 50 to 100 and difference factor (\({\text{f}}_{1}\)) values between 0 to 15% at pH 6.6, thus implying that the brands can be used interchangeably with the innovator brand. The chemical and physical tests carried out reveal that the locally marketed brands of rosuvastatin calcium are of good quality and meet the required regulatory standards.
期刊介绍:
BMC Chemistry, formerly known as Chemistry Central Journal, is now part of the BMC series journals family.
Chemistry Central Journal has served the chemistry community as a trusted open access resource for more than 10 years – and we are delighted to announce the next step on its journey. In January 2019 the journal has been renamed BMC Chemistry and now strengthens the BMC series footprint in the physical sciences by publishing quality articles and by pushing the boundaries of open chemistry.